D. Davidson Easson
Direktor/Vorstandsmitglied bei Worcester Business Development Corp.
Aktive Positionen von D. Davidson Easson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Worcester Business Development Corp. | Direktor/Vorstandsmitglied | 15.03.2010 | - |
University of Massachusetts Medical Center | Direktor/Vorstandsmitglied | 15.03.2010 | - |
JDRF International
JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Direktor/Vorstandsmitglied | 15.03.2010 | - |
Karriereverlauf von D. Davidson Easson
Ehemalige bekannte Positionen von D. Davidson Easson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Alpha-Beta Technology, Inc.
Alpha-Beta Technology, Inc. Electronic ComponentsElectronic Technology Alpha-Beta Technology, Inc. engages in the discovery, development and commercialization of novel carbohydrate-based products for the prevention and treatment of infectious disease. It develops a novel class of immune modulation pharmaceutical products composed of complex carbohydrates and is discovering and developing new anti-fungal diagnostics and drugs. In addition, Alpha-Beta has developed a rapid in vitro diagnostic to detect and monitor systemic fungal infections and has an anti-fungal research program to discover direct inhibitors of fungal cell wall synthesis. It is in the development stage and is devoting substantially all of its efforts toward product research and development, raising capital, marketing products under development, clinical trials and manufacturing. The Company was founded on March 2, 1988 and is headquartered in Worcester, MA. | Geschäftsführer | 15.03.2010 | - |
Gründer | 15.03.2010 | - | |
Treasurer | 15.03.2010 | - |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Director/Board Member | 3 |
Chief Operating Officer | 1 |
Founder | 1 |
Sektoral
Electronic Technology | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Alpha-Beta Technology, Inc.
Alpha-Beta Technology, Inc. Electronic ComponentsElectronic Technology Alpha-Beta Technology, Inc. engages in the discovery, development and commercialization of novel carbohydrate-based products for the prevention and treatment of infectious disease. It develops a novel class of immune modulation pharmaceutical products composed of complex carbohydrates and is discovering and developing new anti-fungal diagnostics and drugs. In addition, Alpha-Beta has developed a rapid in vitro diagnostic to detect and monitor systemic fungal infections and has an anti-fungal research program to discover direct inhibitors of fungal cell wall synthesis. It is in the development stage and is devoting substantially all of its efforts toward product research and development, raising capital, marketing products under development, clinical trials and manufacturing. The Company was founded on March 2, 1988 and is headquartered in Worcester, MA. | Electronic Technology |
Worcester Business Development Corp. | |
University of Massachusetts Medical Center | |
JDRF International
JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Commercial Services |
- Börse
- Insiders
- D. Davidson Easson
- Erfahrung